Regenxbio

REGENXBIO INC

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.

Movers_Stocks

AAOI

AFYA

AKBA

BTBT

CVNA

DOCU

FUTU

GDOT

QBTS

RBRK

RDUS

RGNX

RGTI

SMTC

SOUN

ULTA

Semtech sorprendió al mercado con ingresos y ganancias superiores a lo esperado. Inversores reaccionan ante este sólido desempeño trimestral.

Semtech, Rubrik, DocuSign, PagerDuty y otras acciones estadounidenses que suben el viernes

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AEHR

ATCH

ATPC

AVGR

CANG

CHCI

HCWC

LIDR

NMHI

PHIO

PIII

RIME

SANG

STAF

URGN

YOSH

Las acciones de KB Home suben 9,1% tras superar expectativas de ganancias. Descubre los mayores ganadores y perdedores del mercado hoy.

Las acciones de KB Home se disparan un 9%; 20 acciones que se mueven en el premercado de EE.UU.

Regenxbio Inc

Earnings

Press Releases

REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights

REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II

REGENXBIO to Participate in Upcoming Investor Conferences

REGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITE® Trial of RGX-121 for Treatment of MPS II

Small Cap

REGENXBIO Announces Presentation at the World Muscle Society

REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD

REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting

REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights

REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program

Absci

Akebia Therapeutics

Astria Therapeutics

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences

COMPASS Pathways Plc - American Depository Shares

Compass Pathways

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharma

CytomX Therapeutics

Emergent BioSolutions

Erasca

Gossamer Bio

Gyre Therapeutics

Iovance Biotherapeutics, Inc. - Common Stock

Iovance Biotherapeutics

Inventiva S.A. - American Depository Shares

Inventiva

Lexeo Therapeutics

MeiraGTx Hldgs

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

MapLight Therapeutics, Inc. - Common Stock

MapLight Therapeutics

Myriad Genetics

NovaBridge Biosciences - American Depositary Shares

NovaBridge Biosciences

Anbio Biotechnology - Class A Ordinary Shares

Anbio Biotechnology

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

Prothena Corporation plc - Ordinary Shares

Prothena Corp

RAPT Therapeutics

Rigel Pharmaceuticals, Inc. - Common Stock

Rigel Pharmaceuticals

Verastem

HC Wainwright & Co.

Chardan Capital

RBC Capital

Barclays

Goldman Sachs

Comments

Regenxbio

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL